MacroGenics
Nasdaq MGNX · Rockville, MD
Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
MacroGenics is a clinical trial sponsor based in Rockville, MD, listed as Nasdaq MGNX. It has 5 active clinical trials with 898 planned participants, across 14 therapeutic areas. Since 2021 it has completed 22 trials and stopped 13 early.
Trial track record · since 2021
Financials · Nasdaq MGNX
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about MacroGenics
MacroGenics is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 898 planned participants, in Dermatology, ENT, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 22 trials and stopped 13 early.
MacroGenics is based in Rockville, MD and is listed as Nasdaq MGNX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with MacroGenics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-16.
Approve Suite is not affiliated with MacroGenics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.